CASTLE BIOSCIENCES INC Quarterly Debt-to-equity in % from Q1 2020 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Castle Biosciences Inc quarterly Debt-to-equity history and growth rate from Q1 2020 to Q4 2024.
  • Castle Biosciences Inc Debt-to-equity for the quarter ending December 31, 2024 was 15.6 %, a 19.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 15.6 +2.55 +19.6% Dec 31, 2024
Q3 2024 15.4 +3.32 +27.5% Sep 30, 2024
Q2 2024 14.5 +2.84 +24.4% Jun 30, 2024
Q1 2024 13.8 +3.1 +29% Mar 31, 2024
Q4 2023 13 +2.08 +19% Dec 31, 2023
Q3 2023 12.1 +1.04 +9.44% Sep 30, 2023
Q2 2023 11.6 +2.08 +21.8% Jun 30, 2023
Q1 2023 10.7 +2.17 +25.5% Mar 31, 2023
Q4 2022 11 +4.24 +63.2% Dec 31, 2022
Q3 2022 11 +5.97 +118% Sep 30, 2022
Q2 2022 9.54 +2.07 +27.7% Jun 30, 2022
Q1 2022 8.52 -2.71 -24.1% Mar 31, 2022
Q4 2021 6.71 -10.7 -61.4% Dec 31, 2021
Q3 2021 5.05 -26.1 -83.8% Sep 30, 2021
Q2 2021 7.47 -26.9 -78.2% Jun 30, 2021
Q1 2021 11.2 -54.5 -82.9% Mar 31, 2021
Q4 2020 17.4 Dec 31, 2020
Q3 2020 31.1 Sep 30, 2020
Q2 2020 34.3 Jun 30, 2020
Q1 2020 65.7 Mar 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.